At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RLYB Rallybio Corp.
Not Yet Opened 11-25 16:00:00 EST
1.05
+0.03
+2.94%
盘后1.10
+0.05+4.73%
19:53 EST
High1.10
Low1.05
Vol80.34K
Open1.07
D1 Closing1.02
Amplitude4.90%
Mkt Cap43.56M
Tradable Cap19.92M
Total Shares41.49M
T/O86.51K
T/O Rate0.42%
Tradable Shares18.98M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Rallybio To Provide Update On Rlyb116 Program
BRIEF-Rallybio Announces Approval Of Clinical Trial Applications For Phase 2 Trial Of RLYB212 In Pregnant Women At Higher Risk Of Alloimmunization And FNAIT
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.